72. Remdesivir vs Standard Care in Patients with Moderate covid-19

BACKGROUND: Remdesivir (RDV) shortens time to recovery time in patients with severe COVID-19. Its effect in patients with moderate COVID-19 remains unclear. METHODS: We conducted an open-label, phase 3 trial (NCT04252664) involving hospitalized patients with confirmed SARS-CoV-2 infection, evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Marty, Francisco M, Malhotra, Prashant, Gottlieb, Robert L, Tashima, Karen T, Galli, Massimo, Chai, Louis Yi Ann, SenGupta, Devi, Hyland, Robert H, Wang, Hongyuan, Zhong, Lijie, Cao, Huyen, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Brown, Michael, Goikoetxea, Ane Josune, Jain, Mamta, Hui, David Shu Cheong, Bernasconi, Enos, Spinner, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777983/
http://dx.doi.org/10.1093/ofid/ofaa439.382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777983/
http://dx.doi.org/10.1093/ofid/ofaa439.382

Ejemplares similares